Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by David J. Riley
Cyclophosphamide Versus Placebo in Scleroderma Lung Disease
New England Journal of Medicine
Medicine
Related publications
Correlation of Cough With Disease Activity and Treatment With Cyclophosphamide in Scleroderma Interstitial Lung Disease
Chest
Cardiology
Critical Care
Cardiovascular Medicine
Intensive Care Medicine
Pulmonary
Respiratory Medicine
Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo
Chest
Cardiology
Critical Care
Cardiovascular Medicine
Intensive Care Medicine
Pulmonary
Respiratory Medicine
Cyclophosphamide-Induced Late-Onset Lung Disease.
Internal Medicine
Internal Medicine
Medicine
Interstitial Lung Disease in Patients With Scleroderma: Treatment With Rituximab
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Emphysematous Change With Scleroderma-Associated Interstitial Lung Disease: The Potential Contribution of Vasculopathy?
BMC Pulmonary Medicine
Pulmonary
Respiratory Medicine
Scleroderma Lung Fibrosis and Biologic Drugs
Rheumatology : Current Research
Cyclophosphamide in Disseminated Malignant Disease
BMJ
Inhibition of Thrombin as a Novel Strategy in the Treatment of Scleroderma-Associated Interstitial Lung Disease
Lifitegrast Ophthalmic Solution 5.0% Versus Placebo for Treatment of Dry Eye Disease
Ophthalmology
Ophthalmology
